BioNTech SE
(BSP:B1NT34)
R$
29.34
-0.51 (-1.71%)
Market Cap: 118.71 Bil
Enterprise Value: 34.00 Bil
PE Ratio: 0
PB Ratio: 1.07
GF Score: 53/100 BioNTech SE at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020 / 04:30PM GMT
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Hello, and welcome to all to the UBS Global Healthcare Conference. My name is Navin Jacob, senior analyst, covering large-cap pharma and smid-cap biotech. Our next presentation and fireside chat is with BioNTech, which had a very successful IPO late 2019. I'm very happy to have with me today Chief Strategic Officer, Ryan Richardson. Ryan, thank you for joining us today.
Ryan Richardson
BioNTech SE - Chief Strategy Officer, MD & Member of Management Board
Thank you, Navin.
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
And so -- exactly. So folks on the line, Ryan is going to walk through a few slides here, just to give some backdrop on BioNTech for folks who are not familiar with the name. And then after that, we're going to have a little fireside chat. Go ahead, Ryan.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot